Risk for related mortality increased with urinary cadmium in the 80th versus the 20th percentile in whole population, never smokers in NHANES-III
Tocilizumab Cuts Progression to Ventilation or Death in COVID-19
But death from any cause by day 28 in those hospitalized with COVID-19 pneumonia did not differ for tocilizumab versus placebo
COVID-19 Outcomes Not Improved With Convalescent Plasma
Clinical status, mortality did not differ for convalescent plasma versus placebo in adults with severe COVID-19 pneumonia
- Page 2 of 2
- 1
- 2